Edwards Lifesciences (EW) is back in focus after reporting better than expected adjusted EPS for Q2 2026 and raising its full year 2026 revenue outlook, which has prompted fresh attention on the stock.

At a share price of $92.56, Edwards Lifesciences has seen a 13.74% 90 day share price return and an 18.39% 1 year total shareholder return, suggesting momentum has picked up recently despite a weaker 5 year total shareholder return.

If this kind of earnings driven move has your attention, it may be a good moment to see what else is setting up in healthcare AI. Take a look at the 44 healthcare AI stocks

The recent jump in Edwards Lifesciences after its guidance update has shifted the entry point you are evaluating today. Is the current price already reflecting the improved outlook, or is there still room based on valuation?

Price to earnings premium for Edwards Lifesciences

On a simple snapshot, Edwards Lifesciences looks expensive next to peers. The stock trades on a P/E of 54.4x, while the US Medical Equipment industry sits at 26.4x and the peer group average is 27.8x.

The P/E multiple compares the current share price to earnings per share. For a company like Edwards Lifesciences, it reflects how much investors are willing to pay today for each dollar of current earnings, given its product portfolio in transcatheter valves and structural heart solutions.

Here, the market is assigning a P/E that is more than double both the industry average and the peer average. The estimated fair P/E ratio of 34.8x also sits well below the current 54.4x level, suggesting a valuation that could shift closer to that fair ratio if expectations or sentiment change.

Result: Price-to-earnings of 54.4x (OVERVALUED)

However, Edwards Lifesciences still carries risks if procedure volumes soften or rivals gain share in transcatheter valves, which could pressure both earnings and the current valuation premium.

Another view on Edwards Lifesciences using cash flows

The P/E premium suggests Edwards Lifesciences is priced for high expectations, yet our DCF model paints a more muted picture. At $92.56, the stock sits slightly above an estimated future cash flow value of $91.53, which points to a small degree of overvaluation rather than a deep discount.

If earnings keep tracking close to that cash flow view rather than the P/E premium, the near term upside may be more limited than the headline multiple implies. The question for you is which signal carries more weight right now: the cash flow math or the earnings multiple premium?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Edwards Lifesciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Edwards Lifesciences trading on a premium and the signals looking mixed, it makes sense to move quickly and review the full picture yourself. To see how the positives and negatives stack up in one place, start by checking the 1 key reward and 3 important warning signs

Looking for more investment ideas beyond Edwards Lifesciences?

Do not stop with Edwards Lifesciences. Broaden your watchlist using focused stock ideas that line up with your risk tolerance and return goals, before the next move happens.

• Target potential mispricings by checking out the 51 high quality undervalued stocks that match solid fundamentals and attractive entry points.
• Build a steadier income stream by scanning the 11 dividend fortresses that combine higher yields with robust payout profiles.
• Strengthen the defensive side of your portfolio by reviewing the 88 resilient stocks with low risk scores that carry lower risk scores and resilient characteristics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.